Targeting mTOR pathway inhibits tumor growth in different molecular subtypes of triple-negative breast cancers - Université Paris Cité Accéder directement au contenu
Article Dans Une Revue Oncotarget Année : 2016

Targeting mTOR pathway inhibits tumor growth in different molecular subtypes of triple-negative breast cancers

Sophie Vacher

Résumé

Triple-negative breast cancers (TNBC) are characterized by frequent alterations in the PI3K/AKT/mTOR signaling pathway. In this study, we analyzed PI3K pathway activation in 67 patient-derived xenografts (PDX) of breast cancer and investigated the anti-tumor activity of the mTOR inhibitor everolimus in 15 TNBC PDX with different expression and mutational status of PI3K pathway markers. Expression of the tumor suppressors PTEN and INPP4B was lost in 55% and 76% of TNBC PDX, respectively, while mutations in PIK3CA and AKT1 genes were rare. In 7 PDX treatment with everolimus resulted in a tumor growth inhibition higher than 50%, while 8 models were classified as low responder or resistant. Basal-like, LAR (Luminal AR), mesenchymal and HER2-enriched tumors were present in both responder and resistant groups, suggesting that tumor response to everolimus is not restricted to a specific TNBC subtype. Analysis of treated tumors showed a correlation between tumor response and post-treatment phosphorylation of AKT, increased in responder PDX, while PI3K pathway markers at baseline were not sufficient to predict everolimus response. In conclusion, targeting mTOR decreased tumor growth in 7 out of 15 TNBC PDX tested. Response to everolimus occurred in different TNBC subtypes and was associated with post-treatment increase of P-AKT.

Mots clés

Fichier principal
Vignette du fichier
2016_Hatem_Oncotarget_1 (3.19 Mo) Télécharger le fichier
Origine : Fichiers éditeurs autorisés sur une archive ouverte

Dates et versions

hal-01604166 , version 1 (27-05-2020)

Identifiants

Citer

Rana Hatem, Rania El Botty, Sophie Chateau-Joubert, Jean Luc Servely, Dalila Labiod, et al.. Targeting mTOR pathway inhibits tumor growth in different molecular subtypes of triple-negative breast cancers. Oncotarget, 2016, 7 (30), pp.48206-48219. ⟨10.18632/oncotarget.10195⟩. ⟨hal-01604166⟩
85 Consultations
37 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More